Thomas Gad is Chairman & President at Y-mAbs Therapeutics, Inc. (YMAB). They have made 87 open-market trades across 2 companies since 2019, most recently 2025-09-16.
CIK 0001753224
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 87 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| YMAB | SELL | 2025-03-07 | 2025-03-11 | $5.23 | $113K | +0.2% | -12.8% | +1.8% |
| YMAB | SELL | 2024-09-13 | 2024-09-17 | $13.31 | $1.3M | -9.1% | -0.4% | -30.4% |
| YMAB | SELL | 2024-06-10 | 2024-06-11 | $12.02 | $841K | -1.9% | -2.2% | +8.3% |
| YMAB | SELL | 2024-05-21 | 2024-05-23 | $12.23 | $396K | +3.0% | -2.1% | +12.1% |
| YMAB | SELL | 2024-03-05 | 2024-03-07 | $16.44 | $128K | -15.6% | -18.1% | -27.8% |
| YMAB | SELL | 2023-12-13 | 2023-12-15 | $6.67 | $1.0M | +10.8% | +43.8% | +124.9% |
| YMAB | SELL | 2023-11-20 | 2023-11-22 | $5.31 | $1.2M | +13.3% | +23.7% | +201.5% |
| YMAB | SELL | 2022-02-07 | 2022-02-09 | $7.19 | $4.0M | +14.3% | +31.4% | +45.4% |
| YMAB | SELL | 2022-02-03 | 2022-02-07 | $7.73 | $1.8M | +5.7% | +24.1% | +9.6% |
| YMAB | SELL | 2022-02-01 | 2022-02-03 | $10.15 | $81K | +1.6% | +4.3% | +27.2% |
| YMAB | SELL | 2022-01-24 | 2022-01-26 | $10.63 | $1.9M | -24.7% | -10.5% | -4.4% |
| YMAB | SELL | 2022-01-20 | 2022-01-24 | $11.11 | $4.1M | -26.1% | -26.3% | +3.6% |
| YMAB | SELL | 2022-01-18 | 2022-01-20 | $10.93 | $1.6M | -7.0% | -26.6% | +15.5% |
| YMAB | SELL | 2021-12-06 | 2021-12-08 | $16.83 | $1.1M | -7.4% | -20.2% | -52.0% |
| YMAB | SELL | 2021-11-29 | 2021-12-01 | $17.12 | $1.3M | -2.1% | -1.0% | -43.2% |
| YMAB | SELL | 2021-11-23 | 2021-11-26 | $17.06 | $1.7M | +1.8% | -2.9% | -54.6% |
| YMAB | SELL | 2021-11-16 | 2021-11-18 | $19.33 | $77K | -15.4% | -14.0% | -56.8% |
| YMAB | SELL | 2021-10-29 | 2021-11-01 | $24.82 | $99K | -15.7% | -38.2% | -61.9% |
| YMAB | SELL | 2021-10-15 | 2021-10-19 | $27.20 | $109K | -6.3% | -26.7% | -57.8% |
| YMAB | SELL | 2021-09-30 | 2021-10-04 | $28.26 | $113K | +2.0% | +1.4% | -36.2% |
| YMAB | SELL | 2021-09-15 | 2021-09-17 | $33.64 | $135K | -10.1% | -14.6% | -50.0% |
| YMAB | SELL | 2021-09-02 | 2021-09-07 | $33.18 | $1.7M | +1.6% | -12.5% | -48.0% |
| YMAB | SELL | 2021-08-13 | 2021-08-17 | $29.33 | $1.6M | +2.9% | +17.0% | -24.4% |
| YMAB | SELL | 2021-08-03 | 2021-08-05 | $33.73 | $135K | -26.5% | -18.1% | -29.0% |
| YMAB | SELL | 2021-07-20 | 2021-07-21 | $32.47 | $130K | -0.6% | -17.7% | -23.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.